Advances of AI-driven Drug Design and Discovery in Pharmaceuticals - Review

Dev Ras Pandey ^1*, Sushree Sasmita Dash ¹, Akanksha Mishra ¹

The application of AI in pharmaceuticals holds the promise of personalized therapies, streamlined production, and improved market strategies, making it an indispensable tool for the future of drug development.

Abstract

The field of drug design and discovery is undergoing a transformative shift, leveraging Artificial Intelligence (AI) and Machine Learning (ML) techniques to expedite and optimize the drug development process. Traditional methods are often costly and time-consuming, involving extensive testing and sequential stages. However, contemporary drug development integrates AI, particularly in drug identification and preclinical studies, resulting in significant resource and time savings. AI is utilized for bioactivity and physicochemical forecasting, de novo molecule design, synthesis prediction, and drug-target profile representation. This review introduces the AI-based Drug Design and Discovery System (AI-D3S), a comprehensive approach utilizing serialization, de-serialization, Particle Swarm Optimization (PSO), and Support Vector Machine (SVM). The system demonstrates superior accuracy, precision, sensitivity, and specificity compared to conventional methods, showcasing an average improvement of 8.7%. Our review study evaluates the system on two chemical databases, MAO and Biodegradation, and illustrates its efficacy in predicting drug-annotation combinations. The potential of AI in pharmaceuticals extends from drug design to personalized therapies, decision-making, and efficient resource allocation in marketing. The research envisions AI as an indispensable tool in the pharmaceutical sector, driving innovation, reducing costs, and ensuring the production of higher-quality products. The AI-D3S model presented in this study sets the stage for future advancements in drug design and discovery, offering a promising avenue for the integration of AI in revolutionizing the pharmaceutical industry.

Keywords: Drug Design, Artificial Intelligence, Machine Learning, AI-Driven, Drug Development, Pharmaceuticals

References

Arabi, A. A. (2021). Artificial intelligence in drug design: algorithms, applications, challenges and ethics. Future Drug Discovery, 3(2), FDD59.

https://doi.org/10.4155/fdd-2020-0028

Brown, N., Ertl, P., Lewis, R., Luksch, T., Reker, D., & Schneider, N. (2020). Artificial intelligence in chemistry and drug design. Journal of Computer-Aided Molecular Design, 34, 709-715.

https://doi.org/10.1007/s10822-020-00317-x

Caban, M., Stepnowski, P. (2021). How to decrease pharmaceuticals in the environment? A review. Environ. Chem. Lett. 19, 3115-3138.

https://doi.org/10.1007/s10311-021-01194-y

Duch, W., Swaminathan, K., & Meller, J. (2007). Artificial intelligence approaches for rational drug design and discovery. Current pharmaceutical design, 13(14), 1497-1508.

https://doi.org/10.2174/138161207780765954

Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., Voisin-Chiret, A.S. (2023). PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov. Today. 28(1), 103395.

https://doi.org/10.1016/j.drudis.2022.103395

Guedes, I.A., Barreto, A.M., Marinho, D., Krempser, E., Kuenemann, M.A., Sperandio, O., Miteva, M.A. (2021). New machine learning and physics-based scoring functions for drug discovery. Sci. Rep. 11(1), 3198.

https://doi.org/10.1038/s41598-021-82410-1

Hessler, G., & Baringhaus, K. H. (2018). Artificial intelligence in drug design. Molecules, 23(10), 2520.

https://doi.org/10.3390/molecules23102520

Kolluri, S., Lin, J., Liu, R., Zhang, Y., Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: a review. Arch Aesthetic Plast Surg. 24, 1-10.

https://doi.org/10.1208/s12248-021-00644-3

Kolluri, S., Lin, J., Liu, R., Zhang, Y., Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: a review. Arch Aesthetic Plast Surg. 24, 1-10.

https://doi.org/10.1208/s12248-021-00644-3

Korshunova, M., Ginsburg, B., Tropsha, A., Isayev, O. (2021). OpenChem: a deep learning toolkit for computational chemistry and drug design. J. Chem. Inf. Model. 61(1), 7-13.

https://doi.org/10.1021/acs.jcim.0c00971

Kulkov, I. (2021). The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technol. Soc. 66, 101629.

https://doi.org/10.1016/j.techsoc.2021.101629

Lambrinidis, G., Tsantili-Kakoulidou, A. (2021). Multi-objective optimization methods in novel drug design. Expert Opin Drug Discov. 16(6), 647-658.

https://doi.org/10.1080/17460441.2021.1867095

McComb, M., Bies, R., Ramanathan, M. (2022). Machine learning in pharmacometrics: Opportunities and challenges. Br. J. Clin. Pharmacol. 88(4), 1482-1499.

https://doi.org/10.1111/bcp.14801

Mehta, S. The emerging roles of artificial intelligence in chemistry and drug design. In Data-Driven Technologies and Artificial Intelligence in Supply Chain. 158-173. CRC Press.

https://doi.org/10.1201/9781003462163-9

Mei, S., Zhang, K. (2021). A machine learning framework for predicting drug-drug interactions. Sci. Rep. 11(1), 17619.

https://doi.org/10.1038/s41598-021-97193-8

Mirmozaffari, M., Yazdani, R., Shadkam, E., Khalili, S.M., Mahjoob, M., Boskabadi, A. (2022). An integrated artificial intelligence model for efficiency assessment in pharmaceutical companies during the COVID-19 pandemic. Sustainable Operations and Computers, 3, 156-167.

https://doi.org/10.1016/j.susoc.2022.01.003

Pasrija, P., Jha, P., Upadhyaya, P., Khan, M., & Chopra, M. (2022). Machine Learning and Artificial Intelligence: A Paradigm Shift in Big Data-Driven Drug Design and Discovery. Current Topics in Medicinal Chemistry, 22(20), 1692-1727.

https://doi.org/10.2174/1568026622666220701091339

Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. Drug discovery today, 26(1), 80.

https://doi.org/10.1016/j.drudis.2020.10.010

Ren, P.X., Shang, W.J., Yin, W.C., Ge, H., Wang, L., Zhang, X.L., Bai, F. (2022). A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta Pharmacol. Sin. 43(2), 483-493.

https://doi.org/10.1038/s41401-021-00668-7

Sun, Q., Gong, T., Liu, M., Ren, S., Yang, H., Zeng, S., Xu, H. (2022). Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials, and pharmaceutical research. Phytomedicine. 94, 153805.

https://doi.org/10.1016/j.phymed.2021.153805

Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics, 15(7), 1916.

https://doi.org/10.3390/pharmaceutics15071916

Wang, L., Ding, J., Pan, L., Cao, D., Jiang, H., & Ding, X. (2019). Artificial intelligence facilitates drug design in the big data era. Chemometrics and Intelligent Laboratory Systems, 194, 103850.

https://doi.org/10.1016/j.chemolab.2019.103850

Xiong, J., Xiong, Z., Chen, K., Jiang, H., Zheng, M. (2021). Graph neural networks for automated de novo drug design. Drug Discov. Today. 26(6), 1382-1393.

https://doi.org/10.1016/j.drudis.2021.02.011

Zeng, X., Wang, F., Luo, Y., Kang, S.G., Tang, J., Lightstone, F.C., Cheng, F. (2022). Deep generative molecular design reshapes drug discovery. Cell Rep. Med.

https://doi.org/10.1016/j.xcrm.2022.100794